Great results today, considering the bar was set very high

New Post Public Reply Private Reply Replies (2) Message Board
sox0407
Great results today, considering the bar was set very high to begin with. The dosing was relatively short and only one lesion was being evaluated. If the primary endpoint was one point improvement on the IGA scale instead of two, the response rate should be much higher. In the 200mg arm, the response rate is ~2x of the placebo rate or ~3x if non-compliance is removed, not bad. Response rate could be better with possible higher dosing regimens in the next trial.

Side effects are big concerns for biologics, so no SAE in the 200mg arm is significant. Prurisol will capture some market shares if its efficacy is comparable to other blockbusters in Phase 3. Which one would you rather take? An oral drug without SAEs or a needle with SAEs? I bet at least one BP is smart enough to see the potential.

If P is the riskiest project among the Big Three, K and B will be just fine. The most important takeaway in the PR is that P works in humans and it further validates Dr. Menon’s expertise in pre-clinical studies. The man still has a perfect batting average. Next up, B-OM.

Quote:
Nearly all biotechs developing a psoriasis drug target the moderate-to-severe patient class, but not Cellceutix in its Phase 2 study. Ehrlich explained that the company's confidence in Prurisol led to the decision to evaluate the drug under some of the most difficult situations, and that meant a short-duration study evaluating only one particular lesion in patients being treated with an oral drug (Prurisol). "It doesn't get much more difficult than that," Ehrlich said. "But, by going with a short study, we saved money, challenged our drug, and will have plenty of data for a late-stage trial."

Ehrlich further explained that by taking this approach, Cellceutix is assessing Prurisol's potential for two "huge markets," mild-to-moderate psoriasis and moderate-to-severe psoriasis. "It's a little more savvy approach than one might think at first blush," and one Ehrlich thinks the market may be overlooking.


https://www.thelifesciencesreport.com/pub/na/...al+3-14-16

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Dont-give-up.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 143

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 90

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 83

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 112

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 55

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading

Top 5 Most Recently Viewed Articles

Beyond Finance Secures Legal Win with Permanent Injunction

Updated Category News Views 1608

Legal Victory for Beyond Finance Against Former Executive In a significant legal development, Beyond Finance has successfully secured a permanent injunction against its former Chief Marketing Officer, Grant Eckert. This ruling was handed down by a Texas court, illustrating a firm stance by Beyond Finance in upholding its non-competition agreements. Details of the Case The...

Continue Reading
Analyzing the Decline in Serve Robotics Inc's Short Interest

Updated Category News Views 174

Understanding Serve Robotics Inc's Short Interest Trends Serve Robotics Inc (NYSE: SERV) has recently reported a noticeable decline in its short interest, down by 6.79% from the previous report. As of the latest data, around 13.64 million shares have been sold short, representing 19.08% of all available shares for trading. Notably, it would take traders an average of 1.53...

Continue Reading
FAT Brands Stock Trend Analysis: 52-Week Low Challenges

Updated Category News Views 147

FAT Brands Faces Market Challenges at 52-Week Low In recent trading activities, FAT Brands Inc., trading under the ticker FATBB, has encountered significant market challenges, recently dropping to a 52-week low of $4.13. This recent low is indicative of the difficulties the company is facing amidst a shifting economic environment. Market Dynamics Affecting FAT Brands...

Continue Reading
Kraig Labs Leads the Charge in Revolutionary Silk Fabrication

Updated Category News Views 221

Kraig Labs: Pioneering Spider Silk Innovation In recent years, the realm of biotechnology has witnessed significant advancements, particularly in the production of specialized materials. Kraig Biocraft Laboratories, or Kraig Labs, stands at the forefront of this innovative field, redefining the future of spider silk. This biotechnology company has gained recognition for...

Continue Reading
The Safar Twins Unveil Stunning Short Film Resonance

Updated Category News Views 395

The Safar Twins Unveil a Captivating New Short Film Written and directed by interdisciplinary artist Parsa Afsharjavan, Resonance is an upcoming cinematic gem that promises to captivate audiences worldwide. This 30-minute short film, inspired by the intricate themes of duality and identity, is set to premiere in 2025 and navigate the global festival circuit. Introducing...

Continue Reading